JHBP (CY) HOLDINGS LIMITED
Latest Update:
7 th October, 2020

JHBP (CY) Holdings Limited (" JHBP "or the" Company ";  Stock code: 6998.HK) was officially listed and started trading on the main board of the Stock Exchange of Hong Kong Limited (" THE Stock Exchange of Hong Kong ") at 9:00 a.m. today with a lot of 500 shares.  As the financial public relations consultant team of the company, Porda Havas was fully responsible for the company's public relations and roadshow services, including the maintenance of domestic and foreign media relations, the design and production of listing publicity materials, and the holding of listing celebrations, which helped the company to be listed in Hong Kong successfully.  

Dr. Feng Guo, Executive Director and CEO of JHBP, said, "We are very grateful to investors from all walks of life for their strong support and interest in JHBP.  The listing of JHBP on the main board of the Stock Exchange not only allows the company to step into the international capital market, but also lays a solid foundation for the company's long-term development.  "Looking ahead, our mission is to become a biopharmaceutical engine for innovative therapeutics discovery, research, development, manufacturing and commercialization for the benefit of patients in China and around the world, and we are committed to breaking through the industry, expanding market share and maximizing value for our shareholders."  

Goldman Sachs (Asia) Limited, J.P.Morgan Securities (Far East) Limited and Furey Financial Group Hong Kong Limited are the co-sponsors.  Goldman Sachs (Asia) Limited, J.P.Morgan Securities (Asia Pacific) Limited and Furay Financial Group Hong Kong Limited are the joint global coordinators.  Goldman Sachs (Asia) Limited, J.P. Morgan Securities (Asia Pacific) Limited (public offering in Hong Kong), J.P. Morgan Securities  PLC (international offering) and Furey Financial Group Hong Kong Limited, China Merchants International Finance Limited, Huaxing Securities (Hong Kong) Limited, Haitong International Securities Limited and Macquarie Capital Limited are the joint bookrunners and joint lead managers.  Futu Securities International (Hong Kong) Limited and Tiger Securities of the United States are the joint lead managers.  

About JHBP (Cayman) Holdings Limited (" JHBP ")  

Founded in December 2007, JHBP is a commercialized biopharmaceutical company focusing on the research and development of tumor and autoimmune drugs.  The company is committed to providing accessible medicines to patients whose treatment needs are not being met.  Currently, Jiahe has 15 products in development, including one New Drug Marketing application (NDA) under priority review by the State Medical Products Administration (" NDA "), and two more NDA submissions are expected to be submitted to the STATE Medical Products Administration (" NDA ") in the next 12 to 18 months.  The company's integrated biopharmaceutical platform covers all key drug development functions including exploration, research, clinical development, CMC (chemistry, manufacturing and control) and business development.  The company's management team has an average of more than 15 years of industry experience with global biopharmaceutical companies such as Pfizer, Merck, Amgen and AbbVie.  Under his leadership, the company has established a highly integrated RESEARCH and development team.  With offices and industrial bases in Zhangjiang, Shanghai, Yuxi, Yunnan and Beijing, as well as a research center in San Francisco, THE company currently has nearly 400 employees, about 80% of whom are research and clinical developers. 

Latest Update:
7 th October, 2020